

ABSTRACT

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPP-IV) inhibitor and a biguanide agent in combination, which enhance the effects of active
5 circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).